Neuronoff News
March 16, 2026
Neuronoff Demonstrates Multi-Site IPG Compatibility for Injectrode Platform, Expanding Neuromodulation Beyond Spinal Cord Stimulation
Needle-Delivered Tripolar Electrode Connects to Standard IPG Connectors; Selectively Stimulates Lumbar DRG, Peripheral Nerve, and Sacral Targets from Single Implantable Pulse Generator
October 8, 2025
The funding supports scaling production to 1,000 units annually and preparing for a limited U.S. launch in 2026 targeting interventional pain physicians, spinal surgeons, podiatrists, and other specialties treating chronic pain.
Neuronoff Closes Oversubscribed $4.5M Round to Prepare Launch of Injectrode Platform for Chronic Pain
January 30, 2025
The Department of Defense (DOD) has recommended $1.73 million to fund a clinical randomized controlled trial (RCT) for the treatment of neurogenic bladder following spinal cord injury, while the National Institutes of Health (NIH) has awarded $3.2 million to support preclinical research in overactive bladder treatment.
Neuronoff Secures $5 Million in DOD and NIH Funding to Advance Minimally Invasive Neuromodulation Platform
April 23, 2024
Neuronoff Announces Safety and Functionality Success in First-in-Human Trial of Injectrode for Minimally Invasive Chronic Pain Relief (LIFE study)
The company has successfully completed the first-in-human clinical trial evaluating the safety and effectiveness of its flagship product, the Injectrode, designed to treat chronic pain
January 31, 2024
This milestone in chronic pain management involved two study participants receiving the minimally invasive injectable electrode, targeting peripheral nerve branches in the lumbar lower back — a key area for novel lower back pain treatments.